FINWIRES · TerminalLIVE
FINWIRES

Immutep Says First-in-Human Study Assessing Autoimmune Disease Drug Candidate Meets Primary Endpoint; Shares Down 4%

By

Immutep (ASX:IMM) said a first-in-human phase one study evaluating IMP761, a potential therapeutic option for autoimmune diseases, met its primary endpoint, showing favorable safety and tolerability in healthy volunteers in the single ascending dose part of the study, according to a Thursday filing with the Australian bourse.

IMP761 was designed to target activated T cells at inflammation sites to reduce pathological immune responses while preserving systemic immune function, the filing said.

Early findings showed "significant and clinically relevant" pharmacodynamic activity, including the reduction of local inflammatory responses and attenuated T-cell activity compared with placebo across groups ranging from 0.9 milligrams per kilogram to 7 milligrams per kilogram, per the filing.

Shares fell nearly 4% in morning trade Thursday.

Related Articles

Asia

Hansoh Pharmaceutical's Weight-loss Injection Enters China Review

Hansoh Pharmaceutical (HKG:3692) said China's National Medical Products Administration accepted its application of olatorepatide injection to treat obesity, according to a Thursday filing with the Hong Kong bourse.The drug is meant to be administered once a week.Shares of the company fell nearly 1% in recent morning trade.

$HKG:3692
Asia

Qantas Airways Market Share Trends in Australia Overall Remain Stable, Jarden Says

Qantas Airways' (ASX:QAN) market share trends in Australia overall remain stable at 49%, Jarden said in a Thursday note.Overall, the Australian market is expected to see a snap back in scheduled seats growth through July, up 11% year-over-year, driven largely by a scheduled uplift in seats capacity from Asian discounters and Chinese carriers.Deep capacity reductions for Middle East carriers, which fell 71% through April, but are set to recover over the course of the first half of fiscal year 2027, and restore capacity by June to pre-conflict levels. North American seat growth has remained resilient over the final few months of the second half of fiscal year 2026, based on current scheduled capacity.Based on Visible Alpha consensus estimates, Qantas' international capacity growth is forecast at 2.1% in the first half of fiscal year 2027.The investment firm retained its buy rating and its AU$11.25 per share price target on Qantas.

$ASX:QAN
Asia

Fitch Ratings Affirms Li & Fung's Long-term Credit Rating Following New Advent Acquisition

Fitch Ratings on Wednesday affirmed Li & Fung's long-term credit rating at "BB" after the Hong Kong-based logistics and supply chain company announced an agreement to acquire 55% of New Advent Global for about $250 million.The ratings agency also affirmed L&F's senior unsecured rating at "BB."Fitch said the rating was supported by the company's "unique position as a leading global sourcing and trading platform."The outlook on the rating was stable, reflecting the agency's expectation the acquisition will bolster L&F's business profile.

$^HSI